Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? | Zendy

Konstantin Kletenkov | Zendy; Daniel Hoffmann | Zendy; Jürg Böni | Zendy; Sabine Yerly | Zendy; Vincent Aubert | Zendy; F. Schöni-Affolter | Zendy; Daniel Struck | Zendy; Jens Verheyen | Zendy; Thomas Klimkait | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?

Author(s) -

Konstantin Kletenkov,

Daniel Hoffmann,

Jürg Böni,

Sabine Yerly,

Vincent Aubert,

F. Schöni-Affolter,

Daniel Struck,

Jens Verheyen,

Thomas Klimkait

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw493

Subject(s) - group specific antigen , mutation , drug resistance , protease , mutagenesis , genotyping , pi , resistance mutation , virology , biology , lentivirus , hiv 1 protease , cohort , virus , medicine , genetics , gene , genotype , viral disease , polymerase chain reaction , enzyme , reverse transcriptase , biochemistry

HIV Gag mutations have been reported to confer PI drug resistance. However, clinical implications are still controversial and most current genotyping algorithms consider solely the protease gene for assessing PI resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research